Karolinska Development – Year-End Report 2012, invitation to conference call and webcast Wednesday, February 20

STOCKHOLM - February 18, 2013. Karolinska Development will publish its Year-End Report 2012 at 08.00 CET on Wednesday, February 20. The company will also host a conference call and an on-line presentation on the same day at 14.00 CET.

Please dial in at the following number a few minutes before the start of the conference call:
From Sweden: +46 (0)8 506 307 79, from the US: +1 8 666 828 490, from the UK and other countries: +44 (0) 1452 555 131.

The presentation will also be webcasted and can be accessed from the following web address:
http://storm.zoomvisionmamato.com/player/karolinska_development/objects/fc73maj4/

Host: Torbjörn Bjerke, CEO.

For further information, please contact:
Benjamin Nordin, IRO, Karolinska Development AB

Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 34 projects, of which 15 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

About Us

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.

Subscribe

Documents & Links